Compare ATYR & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | IROQ |
|---|---|---|
| Founded | 2005 | 1883 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 84.4M |
| IPO Year | 2015 | 2011 |
| Metric | ATYR | IROQ |
|---|---|---|
| Price | $0.73 | $26.90 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 2.2K |
| Earning Date | 11-06-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | N/A | ★ 157.16 |
| EPS | N/A | ★ 1.60 |
| Revenue | $190,000.00 | ★ $27,979,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | ★ N/A | $16.78 |
| Revenue Growth | N/A | ★ 24.68 |
| 52 Week Low | $0.64 | $22.84 |
| 52 Week High | $7.29 | $27.01 |
| Indicator | ATYR | IROQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 65.65 |
| Support Level | $0.70 | $26.60 |
| Resistance Level | $0.76 | $26.98 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 32.21 | 86.42 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.